Total Payments
$506.44
2024 Payments
$137.85
Companies
5
Transactions
30
Medicare Patients
2,762
Medicare Billing
$375,836
Payment Breakdown by Category
Food & Beverage$506.44 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $506.44 | 30 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $294.68 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $102.05 | 7 | $0 (2022) |
| PFIZER INC. | $61.99 | 4 | $0 (2024) |
| Merck Sharp & Dohme LLC | $32.96 | 2 | $0 (2023) |
| Novo Nordisk Inc | $14.76 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $137.85 | 8 | ABBVIE INC. ($89.23) |
| 2023 | $127.95 | 7 | AbbVie Inc. ($94.85) |
| 2022 | $123.72 | 8 | ABBVIE INC. ($67.29) |
| 2021 | $102.16 | 6 | E.R. Squibb & Sons, L.L.C. ($58.85) |
| 2020 | $14.76 | 1 | Novo Nordisk Inc ($14.76) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/06/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/11/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/22/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/11/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/20/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/30/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/29/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/05/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/12/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/10/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/11/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/13/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/16/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/15/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/28/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.86 | General |
| Category: Cardiovascular | ||||||
| 10/17/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/28/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/16/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/08/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/25/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Cardiovascular | ||||||
| 05/11/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/02/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.34 | General |
| Category: Cardiovascular | ||||||
| 11/03/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/13/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 692 | 1,052 | $365,802 | $96,969 |
| 2022 | 9 | 704 | 1,107 | $394,445 | $97,632 |
| 2021 | 11 | 952 | 1,458 | $492,861 | $126,188 |
| 2020 | 7 | 414 | 621 | $205,272 | $55,046 |
Total Patients
2,762
Total Services
4,238
Medicare Billing
$375,836
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 194 | 387 | $132,741 | $38,747 | 29.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 171 | 327 | $78,480 | $21,121 | 26.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 187 | 196 | $70,168 | $18,501 | 26.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 60 | 62 | $45,446 | $9,005 | 19.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 69 | 69 | $30,981 | $7,602 | 24.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 11 | $7,986 | $1,993 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 239 | 539 | $183,162 | $46,822 | 25.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 163 | 167 | $58,712 | $14,919 | 25.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 117 | 212 | $50,880 | $12,986 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 61 | 62 | $45,312 | $10,198 | 22.5% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 38 | 39 | $19,188 | $4,316 | 22.5% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $13,460 | $2,917 | 21.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $12,123 | $2,895 | 23.9% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 25 | 25 | $5,832 | $1,425 | 24.4% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 14 | 16 | $5,776 | $1,153 | 20.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 204 | 448 | $153,664 | $40,625 | 26.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 260 | 512 | $122,880 | $32,099 | 26.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 207 | 212 | $75,896 | $19,655 | 25.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 84 | 85 | $56,610 | $14,524 | 25.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 51 | 51 | $22,899 | $5,949 | 26.0% |
| 99219 | Hospital observation care, typically 50 minutes | Facility | 2021 | 46 | 47 | $21,009 | $5,482 | 26.1% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Facility | 2021 | 29 | 29 | $7,968 | $1,976 | 24.8% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 13 | 13 | $7,956 | $1,893 | 23.8% |
| 99217 | Hospital observation care on day of discharge | Facility | 2021 | 23 | 23 | $5,589 | $1,472 | 26.3% |
| 36556 | Insertion of central venous catheter for infusion, patient 5 years or older, not tunneled | Facility | 2021 | 17 | 18 | $13,570 | $1,325 | 9.8% |
About Dr. Gary Devine, D.O
Dr. Gary Devine, D.O is a Internal Medicine healthcare provider based in Hackettstown, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2017. The National Provider Identifier (NPI) number assigned to this provider is 1063943082.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Devine, D.O has received a total of $506.44 in payments from pharmaceutical and medical device companies, with $137.85 received in 2024. These payments were reported across 30 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($506.44).
As a Medicare-enrolled provider, Devine has provided services to 2,762 Medicare beneficiaries, totaling 4,238 services with total Medicare billing of $375,836. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Hackettstown, NJ
- Active Since 03/22/2017
- Last Updated 11/13/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1063943082
Products in Payments
- DALVANCE (Drug) $199.83
- ELIQUIS (Drug) $134.51
- TEFLARO (Drug) $94.85
- DIFICID (Drug) $32.96
- VYNDAQEL (Drug) $15.67
- Ozempic (Drug) $14.76
- CAMZYOS (Drug) $13.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hackettstown
Dr. Sanjay Kavathia, M.d, M.D
Internal Medicine — Payments: $16,054
Internal Medicine $16,054
Dr. Sandira Segaram, M.d., F.a.c.p, M.D., F.A.C.P
Internal Medicine — Payments: $9,446
Internal Medicine $9,446
Dr. Lillian Theune, D.o, D.O
Internal Medicine — Payments: $5,606
Internal Medicine $5,606
Keri Ingrassia-Squiers, Do, DO
Internal Medicine — Payments: $4,471
Internal Medicine $4,471
Vineet Sandhu
Internal Medicine — Payments: $3,129
Internal Medicine $3,129
Jimmy Chang, M.d, M.D
Internal Medicine — Payments: $3,000
Internal Medicine $3,000